Skip to main content
×
×
Home

Differential prevalence and correlates of whole blood Epstein–Barr virus DNA between HIV-positive and HIV-negative men who have sex with men in Shanghai, China

  • R. PAN (a1) (a2), X. LIU (a1), S. ZHOU (a1), Z. NING (a3), H. ZHENG (a4), M. GAO (a1), Y. DING (a1), W. YAO (a2), X. LIAO (a2) and N. HE (a1)...
Summary

This cross-sectional study aimed to examine and compare prevalence and correlates of whole blood Epstein–Barr virus (EBV) DNA between HIV-positive and HIV-negative men who have sex with men (MSM). Five hundred and four HIV-positive MSM and 504 age-matched HIV-negative MSM were recruited from an HIV counseling and testing clinic in Shanghai, China from November 2014 to November 2015 and were administered with a face-to-face questionnaire interview. Whole blood EBV DNA was tested by nested polymerase chain reaction assays on EBNA-1, EBNA-2, and LMP-1 genes. The prevalence of whole blood EBV DNA was 56·0% (95% CI 51·7–60·3%) among HIV-positive MSM and 26·0% (95% CI 22·4–30·0%) among HIV-negative MSM. Whole blood EBV DNA positivity was significantly associated with HIV infection (adjusted odds ratio (aOR) 3·43, 95% CI 2·58–4·57) and frequent intake of pickled, smoked, or salty food (aOR 1·71, 95% CI 1·02–2·86) in the whole sample, and with <200 cells/μl CD4 cell counts (aOR 1·79, 95% CI 1·05–3·05) and pickled, smoked, or salty food intake (aOR 3·14, 95% CI 1·39–7·08) in HIV-positive group. HIV-infected MSM are at higher risk of active EBV replication than HIV-uninfected MSM, underscoring needs of surveillance and research on EBV-related carcinogenesis in this population.

Copyright
Corresponding author
*Author for correspondence: Dr N. He, Department of Epidemiology, School of Public Health, and the Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, P.O. Box 289, 138 Yi Xue Yuan Road, Shanghai 200032, China. (Email: nhe@fudan.edu.cn)
Footnotes
Hide All

Equally contributed first authors.

Footnotes
References
Hide All
1. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. The Lancet 2008; 372: 293299. doi: 10.1016/S0140-6736(08)61113-7.
2. Pantanowitz, L, Schlecht, HP, Dezube, BJ. The growing problem of non-AIDS-defining malignancies in HIV. Current Opinion in Oncology 2006; 18: 469478. doi: 10.1097/01.cco.0000239886.13537.ed.
3. Cheung, MC, Pantanowitz, L, Dezube, BJ. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. The Oncologist 2005; 10: 412426. doi: 10.1634/theoncologist.10-6-412.
4. Engels, EA. Non-AIDS-defining malignancies in HIV-infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities. AIDS (London, England) 2009; 23: 875885. doi: 10.1097/QAD.0b013e328329216a.
5. Younas, M, et al. Immune activation in the course of HIV-1 infection: causes, phenotypes and persistence under therapy. HIV Medicine 2016; 17: 89105. doi: 10.1111/hiv.12310.
6. Ipp, H, et al. Role of inflammation in HIV-1 disease progression and prognosis. Critical Reviews in Clinical Laboratory Sciences 2014; 51: 98111. doi: 10.3109/10408363.2013.865702.
7. Wada, N, et al. Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984–2008. American Journal of Epidemiology 2013; 177: 116125. doi: 10.1093/aje/kws321.
8. Cobucci, RNO, et al. Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review. Journal of Infection and Public Health 2015; 8: 110. doi: 10.1016/j.jiph.2014.08.003.
9. Silverberg, MJ, et al. Cumulative incidence of cancer among HIV-infected individuals in North America. Annals of Internal Medicine 2015; 163: 507518. doi: 10.7326/M14-2768.
10. Amon, W, Farrell, PJ. Reactivation of Epstein-Barr virus from latency. Reviews in Medical Virology 2005; 15: 149156. doi: 10.1002/rmv.456.
11. Punnett, A, Tsang, RW, Hodgson, DC. Hodgkin lymphoma across the age spectrum: epidemiology, therapy, and late effects. Seminars in Radiation Oncology 2010; 20: 3044. doi: 10.1016/j.semradonc.2009.09.006.
12. Pietersma, F, Piriou, E, van Baarle, D. Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients. Leukemia & Lymphoma 2008; 49: 10281041. doi: 10.1080/10428190801911662.
13. Molyneux, EM, et al. Burkitt's lymphoma. The Lancet 2012; 379: 12341244. doi: 10.1016/S0140-6736(11)61177-X.
14. Busson, P, et al. EBV-associated nasopharyngeal carcinomas: from epidemiology to virus-targeting strategies. Trends in Microbiology 2004; 12: 356360. doi: 10.1016/j.tim.2004.06.005.
15. Chua, MLK, et al. Nasopharyngeal carcinoma. The Lancet 2016; 387: 10121024. doi: 10.1016/S0140-6736(15)00055-0.
16. Guo, X, et al. Evaluation of nonviral risk factors for nasopharyngeal carcinoma in a high-risk population of Southern China. International Journal of Cancer 2009; 124: 29422947. doi: 10.1002/ijc.24293.
17. Xue, W-Q, et al. Quantitative association of tobacco smoking with the risk of nasopharyngeal carcinoma: a comprehensive meta-analysis of studies conducted between 1979 and 2011. American Journal of Epidemiology 2013; 178: 325338. doi: 10.1093/aje/kws479.
18. National Cancer Institute. Adult Hodgkin Lymphoma Treatment (PDQ®). 2016: (https://www.cancer.gov/types/lymphoma/patient/adult-hodgkin-treatment-pdq#link/_1).
19. Chihara, D, et al. New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy. Expert Review of Anticancer Therapy 2015; 15: 531544. doi: 10.1586/14737140.2015.1023712.
20. Han, B-L, et al. Systematic review on Epstein-Barr virus (EBV) DNA in diagnosis of nasopharyngeal carcinoma in Asian populations. Asian Pacific Journal of Cancer Prevention 2012; 13: 25772581.
21. Du, X-J, et al. Circulating EBV DNA, globulin and nodal size predict distant metastasis after intensity-modulated radiotherapy in stage II nasopharyngeal carcinoma. Journal of Cancer 2016; 7: 664670. doi: 10.7150/jca.14183.
22. Lei, KIK, et al. Quantitative analysis of circulating cell-free Epstein–Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignancies. British Journal of Haematology 2000; 111: 239246. doi: 10.1111/j.1365-2141.2000.02344.x.
23. Park, JH, et al. Pretreatment whole blood Epstein-Barr virus-DNA is a significant prognostic marker in patients with Hodgkin lymphoma. Annals of Hematology 2016; 95: 801808. doi: 10.1007/s00277-016-2610-5.
24. van Baarle, D, et al. High prevalence of Epstein-Barr virus type 2 among homosexual men is caused by sexual transmission. The Journal of Infectious Diseases 2000; 181: 20452049. doi: 10.1086/315521.
25. Yang, J, et al. Prevalence and mortality of cancer among HIV-infected inpatients in Beijing, China. BMC Infectious Diseases 2016; 16: 82. doi: 10.1186/s12879-016-1416-3.
26. National Health and Family Planning Commission of the People's Republic of China. 2015 China AIDS Response Progress Report. 2015 (http://unaids.org.cn/pics/20160614144959.pdf).
27. Aitken, C, et al. Heterogeneity within the Epstein-Barr virus nuclear antigen 2 gene in different strains of Epstein-Barr virus. The Journal of General Virology 1994; 75: 95100. doi: 10.1099/0022-1317-75-1-95.
28. Parra, B, Slots, J. Detection of human viruses in periodontal pockets using polymerase chain reaction. Oral Microbiology and Immunology 1996; 11: 289293. doi: 10.1111/j.1399-302X.1996.tb00183.x.
29. Wang, W-Y, et al. Consistent sequence variation of Epstein-Barr virus nuclear antigen 1 in primary tumor and peripheral blood cells of patients with nasopharyngeal Carcinoma. Clinical Cancer Research 2002; 8: 25862590.
30. van Kooij, B, et al. Sequence analysis of EBV DNA isolated from mouth washings and PBMCs of healthy individuals and blood of EBV-LPD patients. Journal of Clinical Virology 2003; 28: 8592. doi: 10.1016/S1386-6532(02)00269-X.
31. Wu, C, et al. Results of detection of Epstein-Barr virus DNA in peripheral blood of HIV/AIDS patients. China Tropical Medicine (in Chinese) 2012; 12: 609611.
32. Wang, C, Chen, Y, He, Y. Study on changes of Epstein-Barr in HIV infected patients after highly active antiretroviral therapy. Journal of Medical Forum (in Chinese) 2008; 29: 47.
33. Rubinstein, PG, Aboulafia, DM, Zloza, A. Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges. AIDS (London, England) 2014; 28: 453465. doi: 10.1097/QAD.0000000000000071.
34. Petrara, MR, et al. Epstein-Barr virus load and immune activation in human immunodeficiency virus type 1-infected patients. Journal of Clinical Virology 2012; 53: 195200. doi: 10.1016/j.jcv.2011.12.013.
35. Navarro, J-T, et al. Plasma Epstein-Barr viral load measurement as a diagnostic marker of lymphoma in HIV-infected patients. Medicina Clinica (Barc) 2010; 135: 485490. doi: 10.1016/j.medcli.2010.02.041.
36. Fan, H, et al. Epstein-Barr viral load as a marker of lymphoma in AIDS patients. Journal of Medical Virology 2005; 75: 5969. doi: 10.1002/jmv.20238.
37. Tisi, MC, et al. Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma. Leukemia & Lymphoma 2016; 57: 628634. doi: 10.3109/10428194.2015.1072766.
38. Piriou, ER, et al. Altered EBV viral load setpoint after HIV seroconversion is in accordance with lack of predictive value of EBV load for the occurrence of AIDS-related non-Hodgkin lymphoma. Journal of Immunology (Baltimore, Md.: 1950) 2004; 172: 69316937.
39. Ho, JHC, Huang, DP, Fong, YY. Salted fish and nasopharyngeal carcinoma in southern Chinese. The Lancet 1978; 312: 626. doi: 10.1016/S0140-6736(78)92844-1.
40. Ning, J-P, et al. Consumption of salted fish and other risk factors for Nasopharyngeal Carcinoma (NPC) in Tianjin, a low-risk region for NPC in the People's Republic of China. Journal of the National Cancer Institute 1990; 82: 291296. doi: 10.1093/jnci/82.4.291.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Full text views

Total number of HTML views: 2
Total number of PDF views: 69 *
Loading metrics...

Abstract views

Total abstract views: 273 *
Loading metrics...

* Views captured on Cambridge Core between 5th June 2017 - 15th August 2018. This data will be updated every 24 hours.